Advances in Multiple Sclerosis and Experimental Demyelinating Diseases
15 Angebote vergleichen

Lieferung aus: Schweiz, Sofort per Download lieferbar.
The past decade has witnessed significant advances in the understanding of the pathophysiology of MS and in the development of novel disease-modifying agents (DMA). The use of DMA in the treatment of patients with MS has drastically increased not only in the United States but throughout the rest of the world. Currently, in the United States, most patients given a diagnosis of relapsing-remitting MS are commenced on a DMA. Controversy still exists regarding how early DMA should be commenced and, Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. PDF, 24.12.2007.

Lieferung aus: Deutschland, Sofort per Download lieferbar.
The past decade has witnessed significant advances in the understanding of the pathophysiology of MS and in the development of novel disease-modifying agents (DMA). The use of DMA in the treatment of patients with MS has drastically increased not only in the United States but throughout the rest of the world. Currently, in the United States, most patients given a diagnosis of relapsing-remitting MS are commenced on a DMA. Controversy still exists regarding how early DMA should be commenced and Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. 24.12.2007, PDF.

Von Händler/Antiquariat, Rheinberg-Buch [53870650], Bergisch Gladbach, Germany.
Neuware - Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. 362 pp. Englisch.

buchversandmimpf2000, [3715720].
Neuware - Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. Buch.

Lieferung aus: Deutschland, Versandkostenfrei.
Buchhandlung Kühn GmbH, [4368407].
Neuware - Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. Buch.

Lieferung aus: Deutschland, Versandkostenfrei.
buchZ AG, [3859792].
Neuware - Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. Buch.

Lieferung aus: Deutschland, E-Book zum Download, Versandkostenfrei.
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients., Kindle Edition, Ausgabe: 2008, Format: Kindle eBook, Label: Springer, Springer, Produktgruppe: eBooks, Publiziert: 2007-12-24, Freigegeben: 2007-12-24, Studio: Springer.

Lieferung aus: Schweiz, Sofort per Download lieferbar.
The past decade has witnessed significant advances in the understanding of the pathophysiology of MS and in the development of novel disease-modifying agents (DMA). The use of DMA in the treatment of patients with MS has drastically increased not only in the United States but throughout the rest of the world. Currently, in the United States, most patients given a diagnosis of relapsing-remitting MS are commenced on a DMA. Controversy still, The past decade has witnessed significant advances in the understanding of the pathophysiology of MS and in the development of novel disease-modifying agents (DMA). The use of DMA in the treatment of patients with MS has drastically increased not only in the United States but throughout the rest of the world. Currently, in the United States, most patients given a diagnosis of relapsing-remitting MS are commenced on a DMA. Controversy still exists regarding how early DMA should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. TOC:Benign Multiple Sclerosis - a distinct clinical entity.- Heterogeneity of Multiple Sclerosis pathology.- Genetics of MS.- Mri as a surrogate marker for MS clinical trials.- Mechanisms of Axonal Injury in Experimental Demyelination .- The role of proteolytic mediators of demyelination and repair.- Genetic basis of spontaneous remyelination.- Experimental remyelination in toxic models of remyelination.- Antibody-induced remyelination.- Neuro-imaging of CNS remyelination in humans.- Hormonal influences in MS.- The role of uric acid in demyelination.- Neuromyelitis Optica - clinical syndrome and new autoantibody marker.- Subject index. PDF, 24.12.2007.

Lieferung aus: Deutschland, sofort lieferbar.
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of.

Lieferung aus: Deutschland, Versandkostenfrei.
Advances in Multiple Sclerosis and Experimental Demyelinating Diseases: There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis (MS). From the days of Charcot in the 1800s, MS has been pa- ologically characterized primarily by demyelination that is, the loss of myelin with the relative preservation of axons. Early manuscripts emphasized the inflammatory component, but in many cases, this was not thought to play a major role in the pathogenesis. At the present time, the prevailing concept in MS is that the inflammatory response is critically involved in the destruction of the myelin sheath. This is derived from relatively weak data in humans but primarily based on an experim- tal model of MS known as experimental autoimmune encephalomyelitis (EAE), in which animals are immunized with myelin antigens. These animals usually develop a monophasic disease characterized primarily by inflammation and the relative absence of demyelination. More recently, this experimental model has dem- strated clear evidence of demyelination. This has mostly occurred as a result of the adoptive transfer of antibody directed against one of the myelin-specific proteins, myelin oligodendrocyte glycoprotein (MOG). Englisch, Ebook.